TP53 and neoplasm: As highlighted above, tumor size <2 cm as assessed by ultrasound combined with the absence of abnormal protein 53 (p53 abn) of the ProMisE subtype allows the identification of a large group (approximately 50%) of women with a very low risk of recurrence or disease progression, in whom sentinel node biopsy or adjuvant treatment is unnecessary.